The companies will collaborate for a clinical trial combining compounds from their respective pipelines in NASH.
News
‘Concerning’ levels of non-alcoholic fatty liver disease among young people
A new study has shown an alarmingly high prevalence of non-alcoholic fatty liver disease in young adults.
The Creative Engagement Group ‘strengthens’ offerings, launches Axiom in Europe
The division will combine the Healthcare Communications team in the UK with the US Axiom team.
MSD’s Keytruda granted FDA extension
The approval is based on results from the Phase III KEYNOTE-042 trial.
Latest NHS stats show “strain on an already overstretched system”
Performance improves in some areas and ambulance response times hit target for the first time ever, but A&E admittances are continuing to rise and cancer patients are still waiting too long for treatment.
New Brexit date is a ‘relief’, says NHS Confederation
The UK has been granted a six-month Brexit extension to October 31.
Maintenance immunotherapy disappoints in SCLC
A trial found that overall survival was not significantly prolonged with combination immunotherapy, or with nivolumab alone.
EMA confirms path for Diurnal’s Chronocort despite trial failure
The company is on track to submit a Marketing Authorisation Application in the fourth quarter of 2019.
Medidata launches Acorn AI
The company aims to accelerate the digital transformation of life sciences in the age of precision medicine.
Showcase and develop marketing excellence in this year’s Marketer of the Year competition
The PharmaTimes Marketer of the Year competition offers candidates the unique opportunity to showcase and improve upon their skills via a live head-to-head challenge.
Four million new child asthma cases linked to traffic pollution
13% of all child asthma cases globally can be attributed to NO2 pollution.
J&J’s HONEUR recruits first two data centres
Leicester Royal Infirmary and The Registry of Monoclonal Gammopathies (RMG) will be joining the network.
New at-home test to give fresh insight into IBS
The trial is in the midst of recruiting over 400 patients aged 18-75 years old.
Gyroscope and Orbital to create retinal gene therapy company
The two units belong to Sycona, who will own 82% of the company.
Concerto inks second AI collaboration in a week, teams up with Pfizer
The companies have entered into a precision oncology collaboration.
